Matinas BioPharma Inc.
MTNB | AMEX
$1.51
-$0.39 (-20.53%)
At close: Oct 30, 2026, 3:59 PM ET
$1.19
-$0.32 (-21.19%)
Pre-market:
Nov 2, 2026, 6:02 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 1.1M | 3.19M | 33K | 158.33K |
Cost of Revenue | 456K | 972K | 941K | 16.68M | 14.58M | 14.36M |
Gross Profit | -456K | -972K | 155K | -13.49M | -14.55M | -14.2M |
Operating Income | -6.96M | -20.16M | -23.77M | -24.59M | -24.74M | -24.21M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -10.35M | -24.33M | -22.94M | -21M | -23.28M | -22.45M |
Net Income | -10.35M | -24.25M | -22.94M | -21M | -23.28M | -22.45M |
Selling & General & Admin | 6.88M | 7.76M | 9.43M | 11.1M | 10.19M | 10.01M |
Research & Development | 85K | 11.43M | 14.49M | 16.68M | 14.58M | 14.36M |
Other Expenses | -456K | n/a | n/a | -16.68M | -14.58M | -14.36M |
Operating Expenses | 6.5M | 19.19M | 23.92M | 11.1M | 10.19M | 10.01M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.96M | 20.16M | 24.86M | 27.78M | 24.77M | 24.36M |
Income Tax Expense | n/a | -80K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 364.94K | 324.39K | 289.69K | 289.08K | 280.24K | 262.53K |
Shares Outstanding (Diluted) | 364.94K | 324.39K | 289.69K | 289.08K | 280.24K | 262.53K |
EPS (Basic) | -30 | -74.70 | -79.20 | -45 | -75.60 | -78.45 |
EPS (Diluted) | -30 | -74.70 | -79.20 | -45 | -75.60 | -78.45 |
EBITDA | -9.89M | -19.19M | -22M | -20.64M | -23M | -23.92M |
EBIT | -10.35M | -20.16M | -22.94M | -21M | -23.28M | -24.21M |
Depreciation & Amortization | 456K | 972K | 941K | 356K | 280K | 290.02K |
Add to Watchlist
Select watchlists to add or remove MTNB